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Abstract
Background: Approximately 80 % of mesothelioma specimens have the wild-type p53 gene, whereas they contain
homozygous deletions in the INK4A/ARF locus that encodes p14ARF and the 16INK4A genes. Consequently, the majority
of mesothelioma is defective of the p53 pathways. We examined whether zoledronic acid (ZOL), a third generation
bisphosphonate, and adenoviruses with a deletion of the E1B-55kD gene (Ad-delE1B55), which augments p53
levels in the infected tumors, could produce combinatory anti-tumor effects on human mesothelioma cells
bearing the wild-type p53 gene.
Methods: Cytotoxicity of ZOL and Ad-delE1B55 was assessed with a WST assay. Cell cycle changes were tested with
flow cytometry. Expression levels of relevant molecules were examined with western blot analysis to investigate a
possible mechanism of cytotoxicity. Furthermore, the expressions of Ad receptors on target cells and infectivity were
estimated with flow cytometry. Viral replication was assayed with the tissue culture infection dose method.
Results: A combinatory use of ZOL and Ad-delE1B55 suppressed cell growth and increased sub-G1 or S-phase
populations compared with a single agent, depending on cells tested. The combinatory treatment up-regulated
p53 levels and subsequently enhanced the cleavage of caspase-3, 8, 9 and poly (ADP-ribose) polymerase, but
expression of molecules involved in autophagy pathways were inconsistent. ZOL-treated cells also increased Ad
infectivity with a dose-dependent manner and augmented Ad replication although the expression levels of
integrin molecules, one of the Ad receptors, were down-regulated.
Conclusions: These findings indicated that ZOL and Ad-delE1B55 achieved combinatory anti-tumor effects
through augmented apoptotic pathways or increased viral replication.
Keywords: Mesothelioma, Replication-competent adenovirus, Bisphosphonates, p53
Background
Malignant pleural mesothelioma, developed in the
pleural cavity, is often associated with asbestos exposure
in the patient history [1, 2]. The prognosis remains poor
and mesothelioma is resistant to a number of chemo-
therapeutic and molecular-targeting agents. A novel
therapeutic strategy is thereby required to improve the
prognosis. Mesothelioma has a characteristic genetic
change. Previous analyses showed that approximately
80 % of mesothelioma specimens had a homozygous de-
letion in the INK4A/ARF locus which encoded p14ARF
and the 16INK4A genes, but the p53 genotype was infre-
quently mutated [3, 4]. The genetic defect leads to in-
activation of the p53 pathways and may be linked with
decreased susceptibility to anti-cancer agents.
Bisphosphonates are synthetic analogues of pyrophos-
phates and show high binding affinity to mineralized
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bone matrix [5]. Previous reports showed that bisphospho-
nates produced cytotoxic effects on tumors such as breast
and prostate cancer [6, 7], and these cytotoxic actions were
attributable to a number of mechanisms including apop-
tosis induction and anti-angiogenesis [5, 8]. Zoledronic
acid (ZOL), one of the third generation of bisphospho-
nates, inhibits the farnesyl pyrophosphate synthetase, a key
enzyme in the mevalonate pathway, and depletes isopren-
oid pools, which subsequently results in decreased preny-
lation of small guanine-nucleotide-binding regulatory
proteins (small G proteins) [5]. Consequently, ZOL pre-
vented growth, adhesion or spreading, and invasion of
cancer cells [5, 9]. In our previous study, we demonstrated
ZOL-mediated cytotoxic effects on mesothelioma cells
[10] and showed that ZOL treatments improved cytotox-
icity of adenoviruses (Ad) expressing the p53 gene on
mesothelioma [11]. Further analyses indicated that aug-
mentation of p53 by ZOL was essential in combinatory ef-
fects of ZOL and DNA damaging drugs which included
the first-line anti-cancer agents for mesothelioma [11].
Replicating-competent Ad is a new strategy for cancer
therapy. They can spread and destroy tumors without
deleterious effects in normal tissues [12, 13]. The replic-
able Ad continuously release the progenies from infected
tumors and consequently circumvent low transduction ef-
ficacy. This replicable propensity enhances the cytotoxicity
but host immunity can be inhibitory to the viral spreading.
Ad lacking the E1B-55 kDa molecules (Ad-delE1B55) are
replication-competent and were originally hypothesized to
target only p53-mutated or -null tumors due to the defect
in p53-inactivating E1B-55 kDa protein [14]. Nevertheless,
Ad proteins that are synthesized during the replication
also regulate p53 expression in infected cells at various
levels even in an epigenetic manner [15]. Subsequent
studies in fact showed that Ad-delE1B55-induced cytotox-
icity was not always related to the p53 genotype [16].
Moreover, our previous study showed that Ad-delE1B55
produced cytotoxicity on mesothelioma cells with the
wild-type p53 gene and achieved combinatory anti-tumor
agents with the first-line chemotherapeutic agents [17].
In the present study, we examined whether ZOL and Ad-
delE1B55 could produce combinatory anti-tumor effects on
human mesothelioma cells carrying the wild-type p53 gene.
We speculated that both agents augmented endogenous
p53 levels, which resulted in augmentation of the cytotox-
icity. Furthermore, we analyzed a possible mechanism of
the combination and investigated involvement of apoptotic
pathways and viral replication in the anti-tumor effects.
Methods
Cells
Human mesothelioma cells, MSTO-211H, NCI-H28,
NCI-H226, NCI-H2452 cells, all of which were purchased
from American Type Culture Collection (Manassas, VA,
USA), and EHMES-10 (provided from Dr. Hironobu
Hamada, Hiroshima University, Japan) [18] and were cul-
tured with RPMI 1640 medium with 10 % fetal calf serum.
HEK 293 and A549 cells, derived from American Type
Culture Collection and Dr. Katsuyuki Hamada (Ehime
University), respectively, were cultured with in Dulbecco’s
Modified Eagle’s Medium containing 10 % fetal calf serum.
NCI-H28, NCI-H2452 and EHMES-10 cells are defect-
ive of the p14ARF and p16INK4A genes, and MSTO-211H
and NCI-H226 cells lack the p14 and p16 transcription
(Additional file 1: Figure S1). Sequence analyses showed
that all of them possessed the wild-type p53 gene.
Ad preparation
Replication-competent Ad-delE1B55 (Accession number
for Ad; M73260), in which the 55 kDa molecule-encoding
E1B region (corresponding to 2019–3509 in M73260
sequences) is deleted, and replication-incompetent Ad ex-
pressing the ß-galactosidase (NM066611) (Ad-LacZ) or
the green fluorescent protein gene (U55762) (Ad-GFP)
powered by the cytomegalovirus promoter (KU317610),
were prepared with an Adeno-X expression system
(Takara, Shiga, Japan) and HEK293 cells. The numbers of
virus particles (vp) per ml was estimated with the formula
[absorbance at 260 nm of purified Ad in the presence of
0.1 % sodium dodecyl sulfate].
Cell cycle analysis and Giemsa staining
Cells treated with ZOL (Novartis, Basel, Switzerland) and/
or either Ad-delE1B55 or Ad-LacZ as a control were fixed
in ice-cold 100 % ethanol, incubated with RNase (50 μg/
ml) and stained with propidium iodide (50 μg/ml). The
staining profiles were analyzed with FACSCalibur and
CellQuest software (BD Biosciences, CA, USA). We set
up a gated area for data collection to remove doublets sig-
nals (Additional file 2: Figure S2). For Giemsa staining,
cells treated with ZOL and/or Ad-delE1B55 were treated
with colcemid (10 μg/ml). They were further incubated
with hypotonic buffer and stained with Giemsa solution.
Viability test in vitro
Cells (5 × 103/well) in 96-well plates were cultured with
ZOL and/or Ad-delE1B55 for 5 days. Cell viability was
determined with a cell-counting WST kit (Wako, Osaka,
Japan) and the relative viability was calculated based on
the absorbance without any treatments. Viable cell num-
bers were also counted with the trypan blue dye exclusion
test. Combinatory effects were examined with CalcuSyn
software (Biosoft, Cambridge, UK). Combination index
(CI) values at respective fractions affected (Fa) points,
which showed relative suppression levels of the cell viabil-
ity, were calculated based on the WST assay. CI < 1, CI = 1
and CI > 1 indicate synergistic, additive and antagonistic
actions, respectively.
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Western blot analysis
Cells were cultured with ZOL and/or either Ad-delE1B55
or Ad-LacZ, and the cell lysate was subjected to sodium
dodecyl sulfate polyacrylamide gel electrophoresis. The
protein was transferred to a nylon filter and was hybrid-
ized with antibodies (Ab), against p53 (Thermo Fisher
Scientific, Fremont, CA, USA), phosphorylated p53 at
serine (Ser) 15, Bid (detecting truncated-Bid as well),
caspase-3, cleaved caspase-3, caspase-8, cleaved caspase-8,
caspase-9, cleaved caspase-9, poly (ADP-ribose) polymer-
ase (PARP), Beclin-1, Atg5, LC3A/B (Cell Signaling,
Danvers, MA, USA), cyclin A, cyclin E, type 2/5 Ad E1A
(Santa Cruz Biotech, Dallas, TX, USA), phosphorylated
H2 histone family member (H2AX) at Ser 139 (Biolegend,
San Diego, CA, USA), hexon (Abcam, Cambridge, UK)
and α-Tubulin (Thermo Fisher Scientific) as a loading
control. The membranes were developed with the ECL
system (GE Healthcare, Buckinghamshire, UK).
Infectivity with Ad-GFP and expression of Ad receptors
Cells were infected with Ad-GFP at several vp doses for
30 min and were then washed to remove Ad. Infected
cells were cultured for 48 h and then analyzed for per-
centages of GFP-positive cells with FACSCalibur and
CellQuest software. Cells of which fluorescence was
greater than the brightest 5 % of uninfected cells were
judged as positively stained. For detecting Ad receptors,
cells were stained with anti-coxsackie adenovirus recep-
tors (CAR) (Upstate, Charlottesville, VA, USA), integrin
αvβ3 (Chemicon, Billerica, MA, USA), integrin αvβ5
(Abcam) Ab and the fluorescence intensity was analyzed
with FACSCalibur and CellQuest software.
Virus production
Cells infected with Ad-delE1B55 were treated with or
without ZOL. The cell lysates were examined for the
cytotoxicity with A549 cells and the virus titers were
calculated with the median tissue culture infectious dose
(TCID50) method.
Results
Cytotoxic activities of ZOL and Ad-delE1B55 on
mesothelioma
We investigated possible cytotoxic effects produced by
ZOL or Ad-delE1B55 on 5 kinds of mesothelioma,
MSTO-211H, NCI-H226, NCI-H28, EHMES-10 and
NCI-H2452 cells, which are defective of the p14ARF and
p16INK4A genes or the transcription but possess the wild-
type p53. Cells treated with ZOL showed decreased via-
bility with a similar level (Fig. 1a), whereas the sensitivity
to Ad-delE1B55 was different among the cells and
EHMES-10 cells were resistant (Fig. 1b). Moreover, a
separate experiment and a previous study showed that
p53 of NCI-H2452 cells was truncated [19]. We
therefore focused on MSTO-211H, NCI-H226 and NCI-
H28 cells for further analyses, which were sensitive to
both agents.
We next examined cytotoxicity produced by a combin-
atory use of ZOL and Ad-delE1B55 (Fig. 2a). The com-
bination achieved cytotoxicity greater than a single
treatment. We examined the combinatory effects with
the CalcuSyn software and showed that CI values were
below 1 at most of the Fa points tested (between 0.3 and
0.8 in MSTO-211H and NCI-H226 cells and between
0.4 and 0.9 in NCI-H28 cells). These data indicated that
the combination of ZOL and Ad-delE1B55 achieved
additive or synergistic cytotoxicity in most of the cases.
We noticed that NCI-H226 and NCI-H28 but not
MSTO-211H cells were relatively resistant to ZOL-
mediated cell death assayed with the dye exclusion test
although these cells were similarly sensitive to ZOL in
the WST assay. The discrepancy was derived from differ-
ential measuring systems between the WST assay, de-
tecting production of mitochondria-derived energy, and
the dye exclusion test, detecting membrane permeability.
We then treated NCI-H226 and NCI-H28 cells with
relatively high ZOL concentrations (60–100 μM) to
induce the growth inhibition and cell death in the fol-
lowing experiments. In contrast, the high ZOL concen-
trations completely killed MSTO-211H cells and we
treated the cells at 10 μM. We then examined live cell
numbers assayed with the dye exclusion test (Fig. 2b).
Cell growth was gradually retarded and declined de-
pending on the agents and cells, and the growth inhib-
ition was stronger in the combination than in cells
treated with ZOL or Ad-delE1B55 alone. Replication-
incompetent Ad-LacZ as a control minimally suppressed
the proliferation and did not produce combinatory ef-
fects with ZOL. These data collectively indicated that
ZOL and Ad-delE1B55 achieved combinatory anti-
tumor effects on mesothelioma.
Cell cycle changes induced by ZOL and Ad-delE1B55
We examined cell cycle changes in MSTO-211H and
NCI-H28 cells with flow cytometry (Fig. 3, Tables 1 and
2) since NCI-H226 cells constantly showed relative high
sub-G1 fractions. Ad-delE1B55 treatments increased
hyperploid fractions, more than 4 N populations, and
sub-G1 fractions in MSTO-211H cells, whereas ZOL
increased sub-G1 fractions (Fig. 3a, Table 1). A combin-
atory use of ZOL and Ad-delE1B55 further increased
sub-G1 populations in MSTO-211H cells compared with
treatments of Ad-delE1B55 or ZOL alone, indicating
that combination induced further apoptosis. NCI-H28
cells infected with Ad-delE1B55 showed increased G2/M
phase populations and hyperploid fractions greater than
Ad-delE1B55-infected MSTO-211H cells, and ZOL treat-
ments in NCI-H28 cells augmented S-phase populations
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with minimal induction of sub-G1 fractions (Fig. 3b,
Table 2). Combination of both agents in NCI-H28 cells in-
creased S-phase and greater than treatments with a single
agent, and minimally up-regulated sub-G1 populations.
The increased S-phase fraction in NCI-H28 cells may be
attributable to failure of Ad-delE1B55-infected cells with
the hyperploid fraction to enter into mitosis and conse-
quently the cell cycle were arrested in S-phase and/or G2/
M-phase. We also confirmed the increased S-phase and
G2/M-phase in NCI-H28 cells treated with ZOL and Ad-
delE1B55 with western blot analysis (Additional file 3:
Figure S3). These cells showed decreased cyclin E and en-
hanced cyclin A expression levels, which was compatible
with cells in S-phase entry and in a progress from S- to
G2/M-phase. Cells uninfected or infected with Ad-LacZ
as a control however showed a minimal level of polyploidy
and the sub-G1 fractions did not increase markedly in
both MSTO-211H and NCI-H28 cells with Ad-LacZ.
We also examined nuclear configurations of MSTO-
211H, NCI-H226 and NCI-H28 cells with Giemsa stain-
ing (Fig. 4). These cells treated with ZOL did not show
any changed compared untreated cells. In contrast, Ad-
delE1B55 infections increased cells with enlarged and
condensed nuclei, which suggested increased nuclear
DNA contents and pyknotic changes. Combinatory
treatments also showed the same nuclear changes with
decreased cell numbers, indicating that cell proliferation
was inhibited by the treatments.
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Fig. 1 A growth inhibitory activity of ZOL or Ad-delE1B55 on mesothelioma. a Cells were treated with various concentrations of ZOL for 5 days
and the cell viabilities were measured with the WST assay. The relative viabilities were calculated based on the absorbance without ZOL treatments.
Means of triplicated samples and SE bars are shown (n = 3). b Cells were infected with various amounts of Ad-delE1B55 and the viability was tested
with the WST assay 5 days after the infection. Relative viability was calculated based on uninfected cells. Averages and SE bars are shown (n = 3). We
repeated this assay for 3 times and show representative data
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Molecular changes induced by combination of ZOL and
Ad-delE1B55
We examined a possible mechanism of combinatory
effects produced by ZOL and Ad-delE1B55 in MSTO-
211H cells with western blot analyses (Fig. 5). E1A
became detectable at 24 h after the infection, but the
expression levels were not different from those with add-
itional 10 μM of ZOL (Fig. 5a). We also examined a
possible involvement of autophagy pathways. Beclin-1
expression levels were down-regulated in cells treated
with either Ad-delE1B55 or ZOL at 24 and 48 h, and in
Ad-delE1B55-treated cells at 72 and 96 h. Atg5 expres-
sion levels in cells treated with Ad-delE1B55 or ZOL
minimally decreased at 24 and 48 h but unchanged after
72 h. Both Beclin-1 and Atg5 expression levels in the
combination-treated cells were not different from those
in cells treated with a single agent except Beclin-1 ex-
pression in Ad-delE1B55-treated cells at 96 h. Moreover,
there was no major transition from LC3A/B I to LC3A/
B II accompanied by any treatments including the
B
A
Fig. 2 Combinatory effects produced by ZOL and Ad-delE1B55. a Cells were treated with different concentrations of ZOL and doses of Ad-delE1B55
as indicated for 5 days. As for combination of ZOL and Ad-delE1B55, cells were treated with different concentrations of ZOL and Ad-delE1B at a fixed
dose (MSTO-211H and NCI-H28: 1.5 × 103 vp/cell, NCI-H226: 5 × 103 vp/cell). The cell viabilities were measured with the WST assay. Averages and SE
bars are shown (n = 3). CI values based on the cell viabilities were determined by different Fa points with the CalcuSyn software. We repeated this assay
for 3 times and show representative data. b Proliferation of cells treated with ZOL and/or either Ad-delE1B55 or Ad-LacZ as a control. Cells were treated
with ZOL (MSTO-211H: 10 μM, NCI-H226: 60 μM, NCI-H28: 100 μM) and/or Ad-delE1B55 or Ad-LacZ (MSTO-211H: 4.5 × 103 vp/cell, NCI-H226: 2 × 103
vp/cell, NCI-H28: 3 × 103 vp/cell). Live cell numbers were determined with the dye exclusion test. Averages and SEs are shown. We repeated this assay
for 3 times in total and show representative data. *p < 0.05, compared the ZOL plus Ad-delE1B55-treated group with Ad-LacZ-, ZOL-, Ad-delE1B55-,
ZOL plus Ad-LacZ-treated cells groups
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combination although the expression levels of LC3A/B II
and to less extent LC3A/B I were enhanced in ZOL-treated
cells. In addition, the LC3A/B II expression levels in the
combination corresponded to the levels of between Ad-
delE1B55-treated and ZOL-treated cells. Expression levels
of Beclin-1, Atg5 and LC3A/B were therefore differentially
influenced by the agents. These data collectively indicated
that cytotoxicity induced by ZOL might be partly linked
with autophagy, but Ad-delE1B- and the combination-
induced cell death were irrelevant to autophagy.
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Fig. 3 Representative profiles of cell-cycle progression. MSTO-211H (a) or NCI-H28 cells (b) were treated with ZOL (MSTO-211H: 10 μM; NCI-H28:
80 μM) and/or either Ad-delE1B55 or Ad-LacZ (MSTO-211H: 4.5 × 103 vp/cell; NCI-H226: 2 × 103 vp/cell). The cell cycle progression was analyzed
with flow cytometry at 24, 48 and 72 h after the treatments
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We then examined expression levels of apoptosis-
linked proteins (Fig. 5b). ZOL at 10 μM in MSTO-211H
cells did not influence p53 or phosphorylated p53 levels,
or induce cleavages of caspase-3, −8 and PARP, but
minimally augmented that of caspase-9. In contrast, Ad-
delE1B55-treated cells augmented p53 and phosphory-
lated p53 levels, and cleavages of caspase-3,-9 and PARP,
but not that of caspase-8. Apoptosis by ZOL or Ad-
delE1B55 could thus be differentially activated through
intrinsic or extrinsic pathways. Cells treated with the
combination showed up-regulated p53 expression, p53
phosphorylation, and subsequently enhanced cleavage of
caspase-3, 8, 9 and PARP at a greater level than those
treated with ZOL or Ad-delE1B alone at 24 and 48 h.
The up-regulated expression in the combination was
however not detected after 72 h except the cleavage
PARP. We noticed that Bid expression was down-
regulated in the combination at 96 h, but truncated Bid,
which contributes to the linkage between the death
receptor- and the mitochondria-mediated apoptosis, was
not induced. Interestingly, phosphorylated H2AX mole-
cules, a marker of DNA damages, was augmented in
Ad-delE1B55- and ZOL-treated cells, suggesting that
DNA damages were involved in both type of the cell
death. The combination did not increase the phosphory-
lated H2AX levels greater than the summated levels of
Ad-delE1B- and ZOL-treated cases. These data collect-
ively indicated that the combinatory cytotoxicity at an
early phase up to 48 h was at least partly due to aug-
mented p53 levels and activated downstream apop-
tosis, but activation of the p53 downstream pathways
was less significantly attributable to the cytotoxicity at
the later phase.
Expression of Ad receptors and Ad infectivity after ZOL
treatments
We examined changes of CAR and integrin αvβ3 or
αvβ5 expression levels by ZOL treatments on MSTO-
Table 1 Cell cycle progression of MSTO-211H cells treated with ZOL and/or Ad-delE1B55
Time (hrs) Treatment Cell cycle distribution (% ± SE)
Sub-G1 G1 S G2/M >4 N
24 (−) 2.04 ± 0.04 58.80 ± 0.20 18.17 ± 0.24 20.67 ± 0.31 0.81 ± 0.06
Ad-LacZ 2.90 ± 0.16 57.30 ± 0.19 17.59 ± 0.22 20.97 ± 0.26 1.83 ± 0.04
Ad-delE1B55 2.61 ± 0.16 55.29 ± 0.07 20.41 ± 0.11 20.08 ± 0.27 2.22 ± 0.11
ZOL 2.47 ± 0.05 57.47 ± 0.10 18.34 ± 0.27 20.70 ± 0.22 1.62 ± 0.09
ZOL + Ad-LacZ 3.58 ± 0.17 55.98 ± 0.16 17.94 ± 0.17 20.84 ± 0.10 2.22 ± 0.08
ZOL + Ad-delE1B55 3.72 ± 0.05 53.99 ± 0.11 20.53 ± 0.23 19.42 ± 0.35 3.00 ± 0.09
48 (−) 1.73 ± 0.07 76.54 ± 0.12 8.20 ± 0.03 12.59 ± 0.08 1.18 ± 0.04
Ad-LacZ 1.37 ± 0.08 75.90 ± 0.38 8.60 ± 0.16 12.55 ± 0.33 1.82 ± 0.03
Ad-delE1B55 12.25 ± 0.04 51.87 ± 0.21 12.47 ± 0.13 21.56 ± 0.19 2.32 ± 0.03
ZOL 3.82 ± 0.08 76.77 ± 0.43 6.70 ± 0.09 11.31 ± 0.33 1.60 ± 0.01
ZOL + Ad-LacZ 2.81 ± 0.11 76.08 ± 0.33 7.47 ± 0.12 11.95 ± 0.13 1.96 ± 0.06
ZOL + Ad-delE1B55 19.69 ± 0.18a 47.47 ± 0.19a 15.42 ± 0.44a 15.23 ± 0.35 2.69 ± 0.16
72 (−) 0.96 ± 0.02 87.55 ± 0.01 3.77 ± 0.13 7.26 ± 0.19 0.59 ± 0.05
Ad-LacZ 1.46 ± 0.10 87.58 ± 0.30 2.75 ± 0.05 7.79 ± 0.14 0.51 ± 0.03
Ad-delE1B55 22.52 ± 0.07 43.47 ± 0.18 11.57 ± 0.14 12.89 ± 0.23 10.14 ± 0.23
ZOL 11.19 ± 0.08 76.77 ± 0.28 3.45 ± 0.08 7.93 ± 0.20 0.81 ± 0.12
ZOL + Ad-LacZ 6.44 ± 0.03 80.27 ± 0.15 3.04 ± 0.04 9.66 ± 0.13 0.78 ± 0.04
ZOL + Ad-delE1B55 35.52 ± 0.05a 24.06 ± 0.30a 13.89 ± 0.13b 11.83 ± 0.21 15.41 ± 0.19
96 (−) 1.03 ± 0.07 87.25 ± 0.01 4.43 ± 0.03 6.93 ± 0.06 0.50 ± 0.03
Ad-LacZ 1.16 ± 0.06 87.36 ± 0.28 3.34 ± 0.17 7.65 ± 0.11 0.68 ± 0.04
Ad-delE1B55 12.14 ± 0.27 53.92 ± 0.29 11.93 ± 0.06 13.21 ± 0.27 9.32 ± 0.31
ZOL 9.32 ± 0.11 80.72 ± 0.21 3.98 ± 0.06 5.73 ± 0.07 0.40 ± 0.07
ZOL + Ad-LacZ 8.93 ± 0.17 78.40 ± 0.17 4.22 ± 0.14 7.92 ± 0.13 0.79 ± 0.04
ZOL+ Ad-delE1B55 40.75 ± 0.08a 21.50 ± 0.21a 14.26 ± 0.11b 10.58 ± 0.12 13.59 ± 0.18b
Cells were treated with ZOL (10 μM) and/or either Ad-delE1B55 or Ad-LacZ (4.5 × 103 vp/cell) and cultured for 24–96 h. Cell cycle profiles were analyzed with flow
cytometry. Averages with SEs are shown (n = 3)
ap < 0.01, bp < 0.05; compared between ZOL + Ad-delE1B55-treated cells, and Ad-LacZ, ZOL-, Ad-delE1B55-, ZOL + Ad-LacZ-treated cells
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211H and NCI-H28 cells (Fig. 6a, Table 3). Influence of
ZOL on the expression level, which was shown as mean
fluorescent intensity, was calculated by comparing the
level of ZOL-treated cells and that of untreated cells as a
control (Table 3). ZOL (10 μM) scarcely influenced ex-
pression levels on MSTO-211H cells, whereas ZOL
(80 μM) decreased the levels of integrin αvβ3 and αvβ5
on NCI-H28 cell. We also examined effects of ZOL at
different concentrations with NCI-H28 cells and found
that increased doses of ZOL decreased the expression
levels of integrin in particular αvβ5 (Additional file 4:
Table S1). We could not examine ZOL-mediated effects
on MSTO-211H cells at the high concentrations since
they became dead at these doses.
We then examined Ad infectivity on mesothelioma
using Ad-GFP, replication-incompetent type 5 Ad with
the same receptor usage as Ad-delE1B55 (Fig. 6b). Fluor-
escence intensity of GFP on MSTO-211H cells was not
significantly different after ZOL treatments (10 μM) but
that on NCI-H28 cells increased with ZOL (80 μM). We
also tested the GFP intensity with different ZOL concen-
trations, and the infectivity to NCI-H28 cells increased
in a dose-dependent manner (Additional file 5: Figure
S4). These results indicated that ZOL influenced Ad re-
ceptor expression and infectivity of Ad-delE1B55, but
these Ad receptor expression levels did not directly
correlated with Ad infectivity. Nevertheless, the enhanced
infectivity suggested a certain role in the combinatory
cytotoxicity in NCI-H28 cells.
Effects of ZOL on viral proliferations of Ad-delE1B55
We examined whether the combinatory effects were as-
sociated with increased production of the viral progen-
ies. MSTO-211H and NCI-H28 cells were infected with
Ad-delE1B55 and treated with ZOL, and then the cell
lysate was tested for the viral titers with the TCID50
method using A549 cells (Fig. 7a). The viral production
in MSTO-211H cells remained unchanged except ZOL-
treated cells at 72 h which decreased the production. In
contrast, ZOL treatments in NCI-H28 cells augmented
the viral propagations. Enhanced cytotoxicity by the
combination in MSTO-211H cells were thereby irrele-
vant to production of infectious Ad progenies, whereas
that in NCI-H28 cells could be attributable to the en-
hanced production of viral progenies. We also examined
expression of E1A, the early gene product, and hexon,
one of the late gene product after ZOL treatments
(Fig. 7b). E1A expression in MSTO-211H cells remained
unchanged or decreased with ZOL treatments, and
hexon expression was not markedly different between
ZOL-untreated and ZOL-treated cells. In contrast, E1A
expression in NCI-H28 cells was initially lower in ZOL-
Table 2 Cell cycle progression of NCI-H28 cells treated with ZOL and/or Ad-delE1B55
Time (hrs) Treatment Cell cycle distribution (% ± SE)
Sub-G1 G1 S G2/M >4 N
24 (−) 8.57 ± 0.34 57.61 ± 1.07 15.48 ± 0.53 16.96 ± 0.89 0.92 ± 0.21
Ad-LacZ 0.17 ± 0.02 58.59 ± 0.71 18.33 ± 0.19 22.24 ± 0.39 1.18 ± 0.17
Ad-delE1B55 0.25 ± 0.10 59.35 ± 0.68 20.28 ± 0.08 15.33 ± 0.38 5.45 ± 0.19
ZOL 0.16 ± 0.03 61.76 ± 0.64 25.71 ± 0.31 212.15 ± 0.48 0.89 ± 0.05
ZOL + Ad-LacZ 0.15 ± 0.03 67.62 ± 0.48 21.85 ± 0.35 9.87 ± 0.20 0.96 ± 0.07
ZOL + Ad-delE1B55 0.23 ± 0.03 65.45 ± 0.73 17.33 ± 0.21 14.21 ± 0.38 3.24 ± 0.24
48 (−) 2.79 ± 0.15 75.8 ± 0.13 9.30 ± 0.05 13.66 ± 0.20 0.93 ± 0.06
Ad-LacZ 0.24 ± 0.01 73.42 ± 0.15 9.22 ± 0.21 16.30 ± 0.20 1.08 ± 0.13
Ad-delE1B55 1.17 ± 0.05 1.70 ± 0.22 8.77 ± 0.22 36.84 ± 0.12 51.80 ± 0.28
ZOL 0.86 ± 0.10 58.00 ± 0.54 25.64 ± 0.15 15.28 ± 0.27 0.82 ± 0.11
ZOL + Ad-LacZ 0.70 ± 0.03 60.80 ± 0.20 25.40 ± 0.27 12.92 ± 0.28 0.77 ± 0.03
ZOL + Ad-delE1B55 1.44 ± 0.22 19.93 ± 1.20 47.98 ± 1.01a 1.28 ± 0.32 0.64 ± 0.37
72 (−) 1.06 ± 0.02 76.33 ± 0.64 9.26 ± 0.23 12.68 ± 0.28 0.92 ± 0.21
Ad-LacZ 0.51 ± 0.06 76.20 ± 0.37 8.68 ± 0.26 13.50 ± 0.46 1.41 ± 0.07
Ad-delE1B55 6.67 ± 0.17 2.15 ± 0.23 5.12 ± 0.49 27.45 ± 0.26 59.21 ± 0.85
ZOL 5.67 ± 0.23 59.46 ± 0.21 19.55 ± 0.57 14.86 ± 0.47 1.02 ± 0.07
ZOL + Ad-LacZ 6.07 ± 0.13 61.94 ± 0.30 16.93 ± 0.16 14.56 ± 0.12 0.97 ± 0.11
ZOL + Ad-delE1B55 8.56 ± 0.38a 7.77 ± 0.84 41.33 ± 1.20a 22.49 ± 0.42 20.77 ± 0.11
Cells were treated with ZOL (80 μM) and/or either Ad-delE1B55 or Ad-LacZ (2 × 103 vp/cell) and cultured for 24–72 h. Cell cycle profiles were analyzed with flow
cytometry. Averages with SEs are shown (n = 3)
ap < 0.01; compared between ZOL + Ad-delE1B55-treated cells, and Ad-LacZ-, ZOL-, Ad-delE1B55-, ZOL + Ad-LacZ-treated cells
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treated cells at 24 h than in ZOL-untreated cells, but be-
came greater in ZOL-treated than ZOL-untreated cells
at 48 and 72 h. Hexon expression likewise was up-
regulated by ZOL treatments after 48 h. The E1A and
the hexon expression levels in NCI-H28 cells were
correlated with production of viral progenies.
Discussion
In this study, we demonstrated that ZOL and Ad-
delE1B55 induced growth suppression and the combin-
ation of both agents produced additive or synergistic
inhibitory effects on mesothelioma cells. ZOL and Ad-
delE1B55 induced differential cell cycle changes and the
combinatory effects were achieved through enhanced
apoptosis or increased viral replication. It is the first
report to our knowledge that bisphosphonates and
replication-competent Ad produced combinatory effects.
We noticed that MSTO-211H cells were sensitive to
ZOL with the dye exclusion test, but NCI-H226 and
NCI-H28 cells required a relatively high dose to induce
cell growth suppression although these 3 kinds of cells
were similarly susceptible to ZOL with the WST assay.
We then tested MSTO-211H cells with a low ZOL con-
centration and NCI-H226 and NCI-H28 cells with a
high ZOL doses in other experimental conditions. Cell
cycle analyses showed that Ad-delE1B55 and ZOL pro-
duced differential effects which was characterized by
hyperploidy and S-phase arrest. A precise mechanism of
hyperploidy and S-phase arrest remain currently un-
known, but the present study showed that Ad-infected
N
C
I-
H
22
6
M
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O
-2
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H
(-) ZOL Ad-delE1B55
ZOL+
Ad-delE1B55
N
C
I-
H
28
Fig. 4 Giemsa staining after Ad-delE1B55 infection. Cells were treated with ZOL (MSTO-211H: 10 μM, NCI-H226: 60 μM, NCI-H28: 80 μM) and/or
Ad-delE1B55 (MSTO-211H: 2 × 103 vp/cell, NCI-H226: 1 × 103 vp/cell, NCI-H28: 2 × 103 vp/cell) for 72 h. Nuclear morphological changes were examined
after the Giemsa staining. In Ad-delE1B55-treated cells, small and highly condensed nucleus (solid arrow) and large and uncondensed nucleus (open
arrow) were detected. An upper panel and lower panel are x4 and x10 in magnifications, respectively
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cells induced enlarged nuclei followed by pyknotic con-
figurations, which was compatible with hyperploidy and
apoptotic cell death. In addition, augmented cyclin A
and decreased cyclin E expression suggested induction
of S-phase arrest, and phosphorylation of H2AX indi-
cated activation of a cellular system detecting viral DNA
increase. Hyperploidy could be due to a direct or an in-
direct consequence of accumulated viral DNA and an
activated DNA damage sensor system thereafter. Fur-
thermore, increased S-phase populations could be re-
sulted from impaired cell cycle progression at S- and
G2-phase and from failure of cells to shift into mitosis.
Previous studies in fact reported that ZOL induced S-
phase arrest and that the cell cycle changes were sub-
jected to aberrant signals induced by mutated tumor
suppressor genes [20].
The majority of human mesothelioma possesses the
wild type p53 gene but lacks the p14ARF and the 16INK4A
genes, which subsequently leads to loss of the p53 func-
tions and activation of the pRb pathways, respectively.
ZOL activated endogenous p53 downstream pathways
on mesothelioma even though the cell death did not de-
pend on the p53 pathways in our recent study [10].
Nevertheless, up-regulated p53 levels increased sensitiv-
ity to cisplatin, one of the first-line chemotherapeutic
agents for mesothelioma [11]. Consequently, ZOL facili-
tated DNA damage responses through the activated p53
downstream pathways despite p53 independence of
ZOL-mediated cytotoxicity. On the other hand, Ad-
delE1B55 also augmented endogenous p53 levels and
subsequently activated the p53 functions in p53 wild-
type mesothelioma, which was evidenced by p53
phosphorylation, pRb dephosphorylation and cleavage of
caspases [17]. The present study showed that combin-
ation of ZOL and Ad-delE1B55 increased phosphory-
lated p53 and cleaved caspase-3 and we therefore
A
B
Fig. 5 Expression of molecules linked with cell death. MSTO-211H cells were treated with ZOL (20 μM) and Ad-delE1B55 or Ad-LacZ (3 × 103 vp/
cell) as a control. Cells were cultured for the indicated times. Expression of viral proteins and autophagy pathways (a) and molecules linked with
cell death pathways (b) were examined with respective Ab and α-Tubulin was used as a loading control
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presume it rational to use the agent together from the
viewpoint of activation of the p53 pathways. Moreover,
effects of ZOL on Ad replication also needs to be clari-
fied since viral replication itself induced cytotoxicity to
the infected cells.
The ZOL inhibits prenylation of small G proteins and
consequently suppresses functions of small G proteins
[5, 8–10]. On the other hand, mesothelioma is often de-
fective of the Hippo pathways due to mutation of the
NF/Merlin gene [21, 22]. Loss of NF/Merlin functions
leads to dysregulation of multiple signal pathways, and
up-regulated functions of small G proteins is one of the
uncontrolled regulation. Ras and RhoA family proteins,
one of the major small G proteins, are in fact activated
in malignant mesothelioma and subsequently mitogen-
activated protein kinases are also activated in most of
the mesothelioma cells [10, 23]. ZOL thereby blocks one
of the dysfunctional Hippo pathways and combinatory
effects of ZOL and Ad-delE1B55 can inhibit a possible
cross-talk between NF/Merlin and the p53 pathways in
mesothelioma with deletion of both INK4A/ARF and
NF/Merlin regions.
We examined influence of ZOL on receptor expres-
sion levels and infectivity of Ad. Expression levels of
major Ad receptors, CAR and integrin αvβ3 and αvβ5,
were not affected by ZOL on MSTO-211H cells,
whereas those of integrin but not CAR was down-
regulated in NCI-H28 cells after ZOL treatments. The
differential influence on integrin expression between the
tested cells were not due to ZOL concentrations since
ZOL at 10 μM also decreased integrin levels on NCI-
H28 cells. Interestingly, Ad infectivity in NCI-H28 cells
A
B
Fig. 6 Expression of Ad receptors and infectivity of Ad. a Expression levels of CAR and integrin αvβ3 or αvβ5 molecules on MSTO-211H and NCI-H28
cells were analyzed with flow cytometry. Representative profiles of cells untreated or treated with ZOL (MSTO-211H: 10 μM, NCI-H28: 80 μM) for 48 h
are shown. CAR expression on MSTO-211H cells was always biphasic and both low and high CAR-positive cells were detected Shaded profiles are
those stained with 2nd Ab alone. b Efficacy of Ad infection examined with Ad-GFP. Cells were infected with Ad-GFP (300–3,000 vp/cell) and treated
with or without ZOL (MSTO-211H: 10 μM, NCI-H28: 80 μM) for 48 h. The mean fluorescent intensity of the GFP-positive cells was analyzed with flow
cytometry and expressed with an arbitrary unit. Averages and the SE bars are shown (n = 3)
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was rather enhanced after ZOL treatments despite the
down-regulated integrin expression, indicating that the
integrin as well as CAR did not play a crucial role in the
infection in NCI-H28 cells. ZOL treatments induced alter-
ation of actin fiber structures followed by morphological
changes since small G proteins in particular Rho family
proteins played a role in the organization of actin fibers in
mesothelioma [24]. Moreover, a previous study reported
that ZOL specifically suppressed integrin αvβ3 but not
α5β1 expression through down-regulate focal adhesion
kinase [25]. On the other hand, suppressed αvβ5 expres-
sion, demonstrated in the present study, had not yet been
reported. Down-regulated expression of integrin mole-
cules and enhanced Ad infectivity can be in part attribut-
able to the ZOL-mediated morphological changes, but
inhibition of small G proteins also influences several intra-
cellular signal pathways and may augment infectivity, for
example, due to facilitated viral release into cytoplasm
after binding to the cellular receptors. Ad endocytosis via
integrin molecules in fact requires activation of the lipid
kinase phosphatidylinositol-3-OH kinase, which in turn
augments signaling cascades of both Ras and Rho families
[26]. In addition, RhoA, Cdc42 and Rab6 were targets for
ZOL-induced actions including cell death, cell cycle arrest
and modification of actin fiber structure [24]. These re-
ports collectively suggested that combinatory cytotoxicity
of ZOL and Ad-delE1B55 was linked with suppressed
small G proteins functions. We also presume that increase
infectivity could directly contribute to the enhanced pro-
duction of Ad progenies since ZOL-treated MSTO-211H
cells did not show the increased production but ZOL
treatments augmented the production in NCI-211H cells.
In addition, cells infected with Ad-delE1B55 during the
G1 phase of cell cycle exhibited a reduced rate of viral late
protein synthesis, and produced fewer viral progenies
than cells infected during the S-phase [27]. Cell cycle
arrest at S-phase that was observed in ZOL-treated
NCI-H28 cells can therefore be favorable for enhanced
viral progeny production.
We hypothesized a possible mechanism involved in the
combinatory effects. ZOL increased an expression level of
p53 in MSTO-211H cells, which was induced by Ad-
delE1B55 at 48 h after the infection, and subsequently ac-
tivated apoptotic signal pathways which was evidenced by
up-regulated cleavages of caspase-8, −9 and −3, and PARP
even without Bid truncation. Moreover, the combination
markedly increased sub-G1 populations in MSTO-211H
cells but ZOL did not influence progeny production of
Ad-delE1B55. These data indicated that the combinatory
effects in MSTO-211H cells were attributable to ZOL-
mediated augmented p53 downstream pathways. In con-
trast, ZOL in NCI-H28 cells augmented the viral infection
and the replication, which was also evidenced by elevated
or prolonged expression of E1A and subsequent hexon ex-
pression. A possible mechanism of the up-regulated Ad
infection can be linked with inhibited functions of small G
proteins, and the augmented infection was dependent on
cells. We noticed ZOL-mediated actions were different
among mesothelioma [10, 20] and the present study
showed a differential pattern of cell cycle progression and
Table 3 Expression of Ad receptor molecules after ZOL treatments
Cells Ab ZOL treatment Mean fluorescent intensity (average ± SE) % radio (average ± SE)
MSTO-211H 2nd Ab alone (−) 12.42 ± 0.07
(+) 13.44 ± 0.07 108.19 ± 0.51
CAR (−) 95.21 ± 2.04
(+) 95.86 ± 0.09 100.69 ± 0.09
Integrin αvβ3 (−) 13.59 ± 0.02
(+) 14.67 ± 0.04 107.92 ± 0.04
Integrin αvβ5 (−) 15.64 ± 0.10
(+) 18.12 ± 0.03 115.88 ± 0.64
NCI-H28 2nd Ab alone (−) 11.39 ± 0.03
(+) 11.55 ± 0.86 101.38 ± 0.79
CAR (−) 127.26 ± 0.31
(+) 119.29 ± 0.69 93.73 ± 0.03
Integrin αvβ3 (−) 1006.61 ± 1.24
(+) 718.29 ± 2.33 71.36 ± 0.12
Integrin αvβ5 (−) 44.01 ± 0.09
(+) 22.01 ± 0.03 50.01 ± 0.13
Cells untreated or treated with ZOL (MSTO-211H: 10 μM, NCI-H28: 80 μM) for 48 h were subjected to flow cytometry to detect expression of the cellular receptors
of type 5 Ad. Means fluorescence intensity was expressed as an arbitrary unit and influence of ZOL on the expression levels was expressed as a percent ratio
based on respective ZOL-untreated cases as a control (n = 3)
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varied expression levels of cell surface molecules between
MSTO-211H and NCI-28 cells. These differences are
probably resulted from divergent effects of small G pro-
teins in cellular functions among the cells tested.
Ad-delE1B55 has been approved in China as an anti-
cancer agent for head and neck cancer [28] and ZOL is
used in a clinical setting in many countries. We has also
started a phase I clinical trial with an intrapleural injection
of ZOL for mesothelioma patients, which can maintains a
local concentration of ZOL to achieve cytotoxicity [29].
The present results under these circumstances will be one
of the preclinical or relevant studies for a future clinical
trial with replication-competent Ad and an inhibitor for
small G proteins.
Conclusions
In this study, we demonstrated that ZOL and Ad-delE1B55
induced growth arrest and produced combinatory cytotoxic
effects on p53 wild-type mesothelioma. We also showed
that the combination of ZOL and Ad-delE1B55 produced
anti-tumor effects through enhanced apoptotic pathways
and up-regulated viral replication. These data collectively
suggest a possible cross-talk of small G proteins and Ad
replication-induced cell death in mesothelioma.
Additional files
Additional file 1: Figure S1. Genetic deletion or loss of expression of
the p14 and p16 genes in mesothelioma. (A) Polymerase chain reactions
to detect the INK4A/ARF region, encoding the p14 and p16 genes. The
p14 gene is comprised by exon 1β, 2 and 3, and the p16 is exon 1α, 2
and 3. NCI-H28, EHMES-10 and NCI-H2452 cells were defective of the p14
and p16 genes. (B) Reverse transcription-polymerase chain reactions to
detect the p14 and the p16 transcripts with primers that amplified between
exon 1β and 2 (for the p14) and exon 1α and 2 (for the p16). Met-5A cells
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were used for a
positive and a loading control, respectively. MSTO-211H and NCI-H226 cells
were negative for the p14 and the p16 transcripts. (PPTX 46 kb)
A
B
Fig. 7 Influence of ZOL on viral progeny production. MSTO-211H and NCI-H28 cells were treated with Ad-delE1B55 (MSTO-211H: 4.5 × 103 vp/cell,
NCI-H28: 2 × 103 vp/cell) or in combination of ZOL (MSTO-211H: 10 μM, NCI-H28: 80 μM) and the cell lysate was extracted at the indicated times.
a The viral titers were assayed with the TCID50 method. Averages and SE bars are shown (n = 3). b Expression of E1A and hexon in cell lysate was
probed with respective Ab. An upper band detected with anti-hexon Ab was due to a non-specific reaction and the lower band corresponded to
hexon. α-Tubulin is used as a loading control
Jiang et al. BMC Cancer  (2016) 16:455 Page 13 of 15
Additional file 2: Figure S2. Gate control for data collection to remove
doublet signals in flow cytometry. Cell cycle profiles of untreated cells
were collected with flow cytometry and we set up a gate to collect the
data in FL2-width (FL2-W) and FL2-area (FL-2A) (shown in a rectangle)
and removed cell doublets in the collection processes. (PPTX 70 kb)
Additional file 3: Figure S3. Expression of cyclin E and cyclin A. NCI-H28
cells treated with ZOL (80 μM) and/or either Ad-delE1B55 or Ad-LacZ (2 ×
103 vp/cell) for 48 h were subjected to western blot analysis. Cyclin E and A
expression were probed with respective Ab and α-Tubulin was used as a
loading control. (PPTX 84 kb)
Additional file 4: Table S1. Expression Ad receptor molecules after
ZOL treatments on NCI-H28 cells. (DOCX 21 kb)
Additional file 5: Figure S4. Influence of ZOL on Ad infectivity. NCI-H28
cells were infected with Ad-GFP (300 or 1,000 vp/cell) and were
treated with ZOL as indicated for 48 h. The mean fluorescent intensity of
the GFP-positive cells was analyzed with flow cytometry and expressed with
an arbitrary unit. Averages and the SE bars are shown (n = 3). Data of ZOL at
80 μM are the same as those in Fig. 6b. (PPTX 46 kb)
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